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system indicators
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aSocial & Behavioural Health Sciences Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada; bInternational
Centre for Reproductive Health- WHO Collaborating Centre, Department of Public Health & Primary Care, Ghent University, Ghent,
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ABSTRACT
Background: Access to essential medicines for the world’s poor and vulnerable has made
little progress since 2000, except for a few specific medicines such as antiretrovirals for HIV/
AIDS. Human rights principles written into national law can create a supportive environment
for universal access to medicines; however, systematic research and policy guidance on this
topic is lacking.
Objective: To examine how international human rights law and WHO’s essential medicines
policies are embedded in national law for medicines affordability and financing, and inter-
preted and implemented in practice to promote universal access to essential medicines.
Methods: This thesis consists of (1) a cross-national content analysis of 192 national consti-
tutions, 71 national medicines policies, and legislation for universal health coverage (UHC)
from 16 mostly low- and middle-income countries; (2) a case study of medicines litigation in
Uruguay, and (3) a follow-up report of eight right to health indicators for access to medicines
from 195 countries.
Results: Some, but not all, of the 12 principles from human rights law and WHO’s policy
are embedded in national UHC law and medicines policies (part 1). Even the most
rights-compliant legislation for access to medicines is subject to the unique and incon-
sistent interpretation of domestic courts, which may be inconsistent with the right to
health in international law (part 2). Many national health systems for which data were
available still fail to meet the official targets for eight indicators of access to medicines
(part 3).
Conclusions: International human rights law and WHO policy are embedded in national law
for essential medicines and practically implemented in national health systems. Law makers
can use these findings and the example texts in this thesis as a starting point for writing and
monitoring governments’ rights-based legal commitments for access to medicines. Future
research should study the effect of national law on access to medicines and population
health.
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This is a PhD Review that provides a synthesis of my
doctoral thesis titled ‘The right to health as the basis
for universal access to essential medicines:
A normative framework and practical examples for
national law and policy’. An estimated 400 million
people do not receive essential health services, includ-
ing vaccines and medicines for modern family plan-
ning methods, antiretroviral therapy for HIV, and
tuberculosis treatment. [1] Striking regional dispari-
ties exist for several of these basic health services:
coverage rates are lowest in Sub-Saharan African
and South Asian countries, where one-third of the
world’s population lives. (1) The Lancet Commission
on Essential Medicines Policies identified five key
barriers to universal access to essential medicines:
medicines affordability, sustainable financing, medi-
cines quality, optimal medicines use, and research
and development of needed medicines. (2) This arti-
cle focuses on medicines affordability and financing.
Essential medicines are defined by the World Health
Organization (WHO) as ‘those that satisfy the prior-
ity healthcare needs of the population’. (3) Essential
medicines are chosen considering the local disease
prevalence, efficacy, safety, and comparative cost
effectiveness [2].
Low- and middle-income countries (LMICs) often
have a large proportion of financially-vulnerable peo-
ple who are dependent on government-subsidised
essential medicines provided at public health facilities
without charge or for a nominal fee [3,4]. However,
frequent stock-outs in these facilities force patients to
turn to the private sector, where medicines are
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available but often at a higher price [3,4]. For exam-
ple, as much as 60% of households in low-income,
33% in lower-middle, and 25% in upper-middle
income countries could not afford four commonly
used cardiovascular medicines sold in private phar-
macies [5]. Unaffordable medicines confront house-
holds with potentially catastrophic health spending,
or force families to forgo treatment at the expense of
their health and possibly their livelihood [3,6].
Despite high-level political commitments to improv-
ing the affordability of medicines (i.e. for non-
communicable diseases), access to essential medicines
for the world’s poor has made little progress, except
for a few medicines such as antiretrovirals [7,8].
To address these challenges, universal health cov-
erage (UHC) is an initiative to broaden equitable
access to financial protection and quality essential
health care such that ‘all people have access to needed
health services (including prevention, promotion,
treatment, rehabilitation and palliation) of sufficient
quality to be effective while also ensuring that the use
of these services does not expose the user to financial
hardship’ [9]. UHC offers financial risk protection to
all, including low-income households, by raising
funds from pre-paid insurance (and sometimes gov-
ernment contributions) and reducing households’
reliance on out-of-pocket expenditures [1]. As such,
UHC is an important means for governments to
make quality essential medicines available, accessible,
and affordable to the vulnerable populations, particu-
larly in LMICs, who currently lack access. Universal
access to essential medicines is an integral part of the
right to health and UHC, reflected in the Sustainable
Development Goal (SDG) 3 for health and SDG
Target 3.8 [10].
Essential medicines as part of the right to health
Human rights have the potential to transform social,
political, and legal norms for more equitable access to
medicines [11]. The right to health is legally binding
on the 169 national governments that have ratified
the International Covenant on Economic, Social, and
Cultural Rights (ICESCR). Consequently, these gov-
ernments are legally obliged to protect and promote
health rights in national law (a term I use to convey
‘domestic law’, meaning all law made by all levels of
a government) and policy. The strength of each coun-
try’s compliance varies depending on the standing of
international law in the domestic legal order, and on
the presence and content of national implementing
legislation. [12]. In 2000, General Comment No. 14,
which is an authoritative interpretation of the right to
health by the UN Committee on Economic, Social,
and Cultural Rights, established that States partyhave
the minimum ‘core obligation’ to provide essential
medicines, defined by WHO, with a maximum of
available resources [13]. Core obligations are basic
minimum standards that serve as the foundation of
all other aspects of the right to health [14]. Legal
provisions in national law that include right to health
language can create a supportive environment for
poor patients to claim government -subsidised essen-
tial medicines [15,16]. (‘Legal provisions’ mean the
legal language that is used to articulate underlying
principles for access to medicines.)
National law as an intervention to promote
access to medicines
National law is a powerful intervention that can pro-
mote equitable access to health services and financial
coverage for the most vulnerable people [17]. WHO’s
David Clarke and colleagues explain that ‘a strong legal
framework sets the rules for how the health system
functions, establishes a legal mandate for access to
health services and provides the means by which
a national government can implement universal health
coverage at a population level’ [17]. Indeed, national
governments frequently use legal tools to shape health
systems in response to their available resources and
public health needs. Between 2011 and 2014, 70 coun-
tries sought WHO’s advice for scaling up UHC [18].
Currently, little research investigates whether and
how national law supports universal access to essen-
tial medicines as part of UHC. The first challenge is
the absence of a reliable and up-to-date global repo-
sitory of national health law. There are two pilot
studies from 2010 of language supporting access to
medicines in national constitutions and national leg-
islation [19,20]. These studies were an important first
step to explore national law and medicines provision;
however, the conclusions are limited by shortcomings
in the search strategy, the small sample of 4 countries,
and little recognition for the then-novel UHC con-
cept. In 2017 WHO and its partners published the
report Advancing the right to health: Vital role of the
law, offering general legal guidance for Member
States on a variety of public health laws, yet none
comprehensively cover access to medicines [21]. In
2018, WHO Europe published a collection of medi-
cines reimbursement policies with nine country case
studies [22]. Although these are insightful descriptive
comparisons of policies in practice, this document
lacks a multi-dimensional critical analysis, including
from the perspective of human rights [22]. This pau-
city of evidence and policy advice illustrates how
emergent such legal studies are in the field of phar-
maceutical policy research.
In addition, little is known about to what degree
national governments realise their human rights
obligations to provide essential medicines to those
who can not provide for themselves. A human rights
approach can employ indicators to monitor changes
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in health systems. Three global initiatives have
sought to identify and, where possible, collect access
to medicines indicators; however, none of these
initiatives offer are up-to-date measures of access to
medicines as a part of the right to health. In 2008,
the then-UN Special Rapporteur on the Right to
Health reported on 72 right to health indicators
(including eight indicators of access to medicines)
in 194 health systems. These indicators have not
been updated since 2008 [23]. The Millennium
Development Goals (MDGs) and the SDGs provide
robust data on national measles immunisation rates
from many countries while reporting on essential
medicines availability from very few countries
[24,25,26]. Drawing from the pool of all foregoing
indicators, the Lancet Commission on Essential
Medicines Policies proposed a set of indicators (pub-
lished during the completion of this thesis) and later
supported a call for a global accountability mechan-
ism for monitoring access to essential medi-
cines [3,27].
Aims
The question guiding this thesis is: How has interna-
tional human rights law and WHO’s essential medicines
policy has been embedded in national law and policy for
medicines affordability and financing, and been inter-
preted and implemented in practice to promote universal
access to essential medicines? This thesis aims to offer
first-ever insight into how access to medicines is
framed in the legal provisions of national law and
policy,and to explore tracer indicators that signal
related impacts on access to medicines in health sys-
tems. ‘National law’ is understood to encompass the
written rules adopted by government institutions and
agencies that impose both legally binding legislation,
whereas ‘policies’ are the non-binding documents or
‘soft’ policies, strategies, or plans of action.
The central premise of this thesis is that national
legal frameworks that include principles and language
from international human rights law and WHO’s
essential medicines policies, can remedy the widespread
political indifference in attaining universal access to
essential medicines. This thesis focuses on laws and
policies that could secure access to medicines for poor
people in mostly low- and middle-income countries.
The specific aims of this thesis are:
(1) to collect and critically analyse the content of
different types of national laws and policies
(‘legal architecture’) related to medicines afford-
ability and financing, against the global standards
established in international human rights law
and WHO’s essential medicines policies;
(2) to investigate how robust national laws pro-
moting universal access to medicines (identi-
fied in aim 2) are interpreted in light of
international human rights law by national
courts in judicial decisions (‘lawmaking’);
(3) to understand how national governments rea-
lise their right to health obligations for essen-
tial medicines by updating the 2008 UN
Special Rapporteur on the Right to Health’s
report on eight right to health indicators of
access to medicines in 195 health systems
(health ‘environment’).
Conceptual framework
To illustrate why national law and policy, and health
systems indicators are relevant for understanding
access to medicines and related health outcomes, this
thesis employs a modified version of Scott Burris and
colleagues’ model to study the effect of national law
and policy on population health [28,29]. See Figure 1.
In this model legal architecture refers to national legis-
lation and policy, understood to be the written and
unwritten rules that can impact on public health. In
the context of access to medicines, ‘legal architecture’
may include domestic constitutions, legislation and
regulation for universal health coverage and public
health, and policies (i.e. national medicines policy
(NMP), national health strategy or plan of action, etc.).
The mediators in the model are the legal practices
of actors (i.e. healthcare professionals, police, etc.)
and institutions that give laws meaning and translate
them into practice. For example, legal practices are
those actions of physicians who give effect to generic
substitution laws or policies by prescribing medicines
by international non-proprietary name.
Legal practices can lead to two types of outputs:
changes in health system performance, or the envir-
onment, and changes in an individual or
a population’s health behaviour. The environment
refers to the physical surroundings, social structures,
and institutions related to health, which are affected
by fluctuations in the available resources (ex. public
Figure 1. Model of the effect of national law on access to
medicines and population health, modified from Scott Burris
and Alexander Wagnaar. The objectives of this thesis are
situated at aims 1, 2, and 3 in the model.
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funding for the provision of essential medicines can
increase access to medicines), rights and obligations,
and incentives and penalties (ex. incentives for phar-
macies to dispense generic medicines to patients)
[29]. Changes in the health environment aim to
achieve a number of goals, which, for essential med-
icines, include helping people access medicines, and/
or enforcing medicines-related laws and policies [29].
Health behaviour. is either directly affected by legal
practices or indirectly through changed environ-
ments, both of which make particular behaviours
more or less attractive. For example, legislation that
changes the health environment by requiring the
government to subsidise the cost of essential medi-
cines for patients, could consequently also increase
patient demand for these medicines, changing their
health behaviour.
A feedback loop exists where changes in the envir-
onment influence lawmaking, known as the activities
of legal actors (i.e. legislative and judicial branches,
policy makers in other areas of the health system)
that result in written and unwritten rules. Lawmaking
includes the actors and the factors that determine
which laws are adopted, and the characteristics and
interpretation of those laws [29]. For example,
national law (the legal architecture) requires the pro-
vision of government-funded essential medicines (the
health environment), which may increase patient
demand for those and other non-essential medicines
(health behaviour). In Latin America, patients turn to
the courts to request publicly-funded medicines that
are not currently accessible/affordable. In these cases,
the domestic court interprets the original domestic
law in light of constitutional rights and obligations to
determine if the patient’s request for medicines
should be granted, which is the process of lawmaking.
The key outcomes in this model are changes in
population health, such as rates of morbidity or
mortality.
Methods
This thesis is a multidisciplinary inquiry drawing
from the legal and health science disciplines. This
synthesis consists of three parts: (1) qualitative docu-
ment analysis of different types of national laws and
national medicines policies, (2) a case study of law-
making in Uruguay, and (3) a quantitative report of
right to health indicators for access to medicines from
195 countries. Methodological aspects of these three
parts are summarised in Table 1.
Analytical frameworks
This thesis derives its analytical framework from the right
to health as it is conceptualised in the ICESCR (article 12)
and elaborated in General Comment No. 14. General
Comment No. 14 is an authoritative interpretation of
the right to health in the ICESCR; it is a non-binding
document that instructs States onwhich aims and actions
will realise their legal obligations in the ICESCR.
Part 1 applies two analytical frameworks that are
appropriate to the scope, content, and detail of the
different types of law under investigation.
Constitutions are analysed through the lens of the
tripartite typology, where the State has a duty to
respect, protect, and fulfil access to medicines as part
of the right to health [13,37]. Respect and protect are
negative duties to refrain from interference and to
safeguard individuals from the actions of third par-
ties, respectively. Fulfil is a positive duty to take steps
to ‘progressively realise’ the right to health, such as
through the provision of health facilities, goods, and
services. Progressive realisation is an obligation to
take deliberate, targeted, and concrete steps towards
realising the right to health.
The detail of national medicines policies and UHC
legislation in part 1 lends itself to a deeper analyses using
the 12-point policy checklist previously developed by the
author and three colleagues as part of this thesis [38,14].
See Table 2. This policy checklist is based on overlapping
principles in WHO’s policies for essential medicines and
international human rights law that are important for
access to medicines. Principles were drawn from
WHO’s essential medicines policies, specifically for med-
icines affordability and the financial protection of vulner-
able groups [39,40,41,42,43], and from international
human rights law in relation to States’ obligations
towards social or health rights, the core obligation to
provide essential medicines, and/or rights related to
good governance [12,40,41,42,43,44,45,46,47]. The nor-
mative development of this 12-point policy checklist is
described elsewhere [38,14]. It serves as a global norma-
tive framework that is both a checklist and a wish list to
evaluate State action to provide essential medicines.
In part 2, the analytical framework applies two
core obligations under the right to health: the State
duty to provide essential medicines, and the State
duty to ensure access to health goods (including but
not limited to diagnostics, devices, technologies, and
medicines, which are the focus of this article) on
a non-discriminatory basis [13,48].
In part 3, the analytical framework matches right
to health principles with corresponding public health
data to gauge the realisation of human rights stan-
dards in a population [49]. Each indicator corre-
sponds to a specific State obligation under the right
to health and has a global target, usually established
by WHO. See Table 3.
Part 1: ‘legal architecture’ for access to medicines
Part 1 is a mapping study of national law and policy,
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legal provisions related to medicines. The subject of
study is written, formalised national law, which
includes all available constitutions and UHC legisla-
tion related to medicines from a purposive sample of
16 mostly LMICs (Algeria, Chile, Colombia, Ghana,
Indonesia, Jordan, Mexico, Morocco, Nigeria,
Philippines, Rwanda, South Africa, Tanzania,
Turkey, Tunisia, Uruguay), as well as all retrievable
full-text national medicines policies adopted by 2015.
The 16 countries each have a universal health cover-
age scheme (at an early, intermediate, or advanced
stage), have ratified the ICESCR, and represent
a diversity of legal traditions, income economies
and world regions. The country selection was also
in function of the research assistants’ language cap-
abilities and the presence of binding, federal UHC
legislation. This explains why the selection does not
include any of the ‘BRICS’ nations (Brazil-Russia-
India-China-South Africa) except South Africa.
Although not representative of all LMICs with
UHC, other countries should be able to learn from
the examples of a comparable country in this sample.
This study also compared the number and strength
of the 12 principles in national medicines policies
adopted before (n = 32) and after (n = 39)
January 1st, 2004. The year 2004 was selected as a cut-
off year because WHO’s latest guidance document for
developing a national medicines policy (2nd edition)
was published in 2001 and the author estimated a lag-
time of two years (i.e. 2002–2003) would be reason-
able for national governments to introduce principles
from the 2001 document into the content of subse-
quent national policies. Associations were determined
in SPSS version 25 using Pearson’s Chi-squared sta-
tistic with significance of p < 0.05.
English-language translations of constitutions were
sourced from the Constitute Project [52]. In the
absence of a global repository of national health law,
a structured online search (i.e. mapping exercise) was
used. Electronic copies of the NMPs and UHC laws in
Table 2. 12-point policy checklist for access to essential medicines applied to in national law. Data sources: 50–51.
Checklist







Countries with strong provisions in UHC legislation for
medicines affordability and financing for vulnerable groups
1. Right to health 13/71 countries (18.3%) 9/16 countries (56.3%) Text includes a universal entitlement to health coverage
includes medicines: Colombia, Chile, Ghana, Indonesia,
Mexico, Nigeria, Tunisia, Turkey, Uruguay
2. State obligation to
provide essential
medicines
17/71 countries (23.9%) 8/16 countries (50.0%) Text includes an absolute State obligation to realise or
guarantee UHC and (affordable) access to medicines:
Colombia, Chile, Ghana, Indonesia, Mexico, Philippines, South
Africa, Uruguay
3. Transparency 19/71 countries (26.8%) 3/16 countries (19.8%) Text requires that information or transparency about medicines




2/71 countries (2.8%) 3/16 countries (19.8%) Text includes the principle of and a mechanism for the
participation or consultation of patients or users in medicines
policies: Chile, Colombia, Mexico
5. Monitoring &
evaluation
15/71 countries (21.1%) 2/16 countries (12.5%) Text requires the State to monitor the affordability and/or




0/71 countries (0%) 9/16 countries (56.3%) Text includes the principle of or right to accountability as well as
a non-judicial mechanism for patients to make complaints or
seek redress: Algeria, Chile, Indonesia, Mexico, Nigeria,
Philippines, Rwanda, South Africa, Turkey
7. Selection of
essential medicines
44/71 countries (62.0%) 7/16 countries (43.8%) Text includes the principle of and a mechanism for (essential)




24/71 countries (33.8%) 5/16 countries (31.3%) Text includes a clear State obligation to finance essential
medicines or medicines in a UHC benefits package: Chile,
Colombia, Mexico, Nigeria, Philippines, Turkey
9. Pool user
contributions
5/71 countries (7.0%) 11/16 countries (68.8%) Text requires the compulsory pre-payment of UHC contributions
with exceptions for those who can not pay: Colombia, Chile,






12/71 countries (16.9%) 1/16 countries (6.3%) Text requires that the State seek financial aid and/or technical
assistance from the international community: Mexico
11. Efficient and cost-
effective spending
43/71 countries (60.6%) 7/16 countries (43.8%) Text includes the principle of cost-effectiveness and/or
efficiency, as well as one or more mechanisms applying these
principles to medicines (i.e. health technology assessment):





17/71 countries (23.9%) 9/16 countries (56.3%) Text includes a clear State duty to finance a UHC package and/
or essential medicines for vulnerable people: Chile, Colombia,
Ghana, Indonesia, Jordan, Mexico, Philippines, South Africa,
Uruguay
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the original language were crowdsourced. Multilingual
researcher assistants – often working in multidisciplin-
ary teams from the Faculties of Medical Sciences and
Law – compiled in-depth, descriptive country profiles
using a template that detailed the national demo-
graphics, health system structure and function, and
legislation in relation to UHC and access to medicines.
Research assistants fluent in the national language pro-
duced unofficial translations of legislation and policy
when official English translations were not available.
Translations for UHC law were peer reviewed by
a second research assistant, except for Jordan and
Turkey. At least one local pharmaceutical policy expert
per country was consulted to verify the accuracy, rele-
vance, and completeness of the primary sources and
country profiles. No peer reviewers were located from
Algeria or Nigeria in the author’s and supervisors’
broader network of access to medicines professionals.
Legal provisions were located by using explicit
search terms and through a manual search of each
document. Constitutional text was identified, cate-
gorised using the abbreviated framework of analysis,
and reviewed by two pharmaceutical policy and
human rights experts. For national policy and UHC
legislation, two researchers coded the excerpts from
national medicines policies and UHC legislation
using explicit definitions defined in the 12-point pol-
icy checklist. The researchers deliberated any coding
differences until consensus was reached.
Part 2: ‘lawmaking’ for access to medicines
through uruguayan courts
Part 2 is a single-country case study of lawmaking by
the Uruguayan appeals courts. It critically analyses
whether and how human rights arguments are used
by the Uruguayan judiciary in relation to patients’
claims for access to specific publicly-financed medi-
cines. Uruguay was selected as a case study because
the State has ratified the ICESCR, it has equity-based
UHC legislation that includes a State obligation to pro-
vide and an individual right to access medicines on
a positive reimbursement list (determined in part 1),
and the right to health is justiciable in national courts.
All retrievable writ of amparo cases claiming
a pharmaceutical intervention and decided in 2015
were included in this study. A writ of amparo is
a judicial procedure that individuals can use to claim
that their fundamental constitutional right(s) are at
immediate and significant risk. These procedures
usually need to be decided within one week of filing
[48]. This selection offers a snapshot of legal interpre-
tation by the courts at the peak of medicines litigation
in Uruguay and in the period immediately following
legal reform designed to curb medicines litigation.
Cases were retrieved from the official Uruguayan
national judiciary online databank (keywords ‘acceso’
and ‘medicamento’). Key facts of each case were
extracted for analysis, including the facts of the case
(i.e. medicine claimed, indication, reimbursement
status, etc.), relevant laws and rights invoked in the
case, and the legal arguments in the court’s decision.
Part 3: access to medicines indicators in the
health system ‘environment’
Part 3 is a follow-up report of the eight right to health
indicators that were chosen by the UN Special
Rapporteur on the Right to Health to reflect access
to essential medicines, from 195 countries [23]. See
the eight right to health indicators in Table 3. In
addition, this study examines the feasibility of using
these indicators as dependent variables to evaluate
the impact of national law and policy.
Data for 195 countries was collected through sys-
tematic online searches and authoritative secondary
online datasets. This article compares median
Table 3. Eight right to health indicators of access to medicines. Data source: 48.
Type of
indicator Right to health indicator [23]
Human rights principle in
General Comment No. 14 [13] Global target
Structural 1. Constitutional commitment to
medicines
Legal obligation to realise health rights Medicines recognised in national
constitutions [50]
2. National medicines policy Duty to adopt a national health plan National medicines policy is adopted [39]
Process 3. National essential medicines list Duty to adopt appropriate administrative measures to
a maximum of its available resources.
(Assured) quality of health services (of the AAAQ)
National essential medicines list is adopted
[50]
4. Government spending on
pharmaceuticals
Financial accessibility of health services (of the AAAQ) US$ 12.90–25.40 per capita per year [3]
Outcome 5. Essential medicines availability in
the public sector
Availability of health services (of the AAAQ) 80% average national availability in both
sectors [50]
6. Essential medicines availability
in the private sector
7. National child immunisation rate
for measles
Duty towards non-discrimination and attention to the
vulnerable
95% coverage with a measles-containing
vaccine to eradicate disease [51]
8. National child immunisation rate
for the third dose of DTP
90% coverage of 3 doses of DTP vaccine to
eradicate disease [50,51]
This table is derived in part from an article published in Global Public Health, 6 September 2018, copyright Taylor & Francis available online at https://
doi.org/10.1080/17441692.2018.1515237.
Abbreviations used in this table: AAAQ = Availability, Accessibility, Acceptability, and Quality as elements of health services under the right to health.
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achievements of countries grouped by income econ-
omy (World Bank definition) on each indicator to the
established global targets (see Table 3). Country-level
achievements on all eight indicators and historical
trends (between the original 2008 report and this
follow-up report) are reported elsewhere [53].
Results
Part 1: ‘legal architecture’ for access to medicines
Example texts from national law and national medi-
cines policies that express human rights duties to
provide essential medicines in legal language are pro-
vided elsewhere [37,38].
Constitutions
Twenty-two constitutions included the duty to pro-
tect and/or to fulfil access to essential medicines;
these commitments were not mutually exclusive.
The duty to protect requires the State to safeguard
individuals from possible deleterious actions of third
parties. In the case of medicines, 14/192 national
constitutions required governments to regulate phar-
maceuticals or monitor their quality, and/or ensure
that access to medicines is not restricted by interna-
tional trade agreements and commercial rights.
Thirteen of 192 national constitutions embed
a State obligations to provide medicines, vaccina-
tions, and/or essential goods (duty to fulfil) as part
of the right to health. No constitution obliges the
State to respect the provision of essential medicines
(i.e. Respecting essential medicines could entail the
government not interfering with access to specific
classes of medicines such as contraception or for
medical abortion) [54]. Full results are reported else-
where [37].
National medicines policies
Seventy-one full-text national medicines policies were
retrieved. See Figure 2. Of the 12 principles, those of
essential medicines selection (62.0% of national med-
icines policies) and efficient spending/cost-effectiveness
(60.6%) were most frequently embedded in policies.
See Table 2. Pooling user contributions (7.0% of
national medicines policies), participation of benefici-
aries (2.8%), and accountability and redress (0%) were
infrequent in many policies. Commitments to medi-
cines affordability and financing are strongest in the
policies of South Africa (1996), Suriname (2005), the
Philippines (2011–2016), El Salvador (2011), and
Somalia (2013).
Some principles that appeared for first time in
the second edition of WHO’s guidelines for medicine
policies (published in 2001), are significantly more
frequent in national medicines policies adopted in
2004 or later. These principles are: the right to health
(n≤2003, = 0/32 policies, n≥2004 = 13/39 policies,
p = 0.000), government financing (n≤2003, = 6/32 poli-
cies, n≥2004 = 18/39 policies, p = 0.015), efficient
spending/cost-effectiveness (n≤2003, = 14/32 policies,
n≥2004 = 29/39 policies, p = 0.009), and financial
protection of vulnerable populations (n≤2003, = 4/32
policies, n≥2004 = 13/39 policies, p = 0.041). Full
results are reported elsewhere [55].
National legislation for universal health coverage
One hundred UHC and medicines-related laws were
retrieved for 16 countries. The principles most fre-
quently legalised in national law were pooling user
contributions (in legislation from 68.8% of countries
studied), accountability (in 56.3%), the right to health
(56.3%), financial protection of vulnerable populations
(56.3%), State obligation (50.0%). See Table 2. The
least common principles were for transparency (in
legislation from 19.8% of countries studied), partici-
pation (19.8%), monitoring (12.5%), and international
assistance and cooperation (6.3%). Overall, UHC leg-
islation from Colombia, Chile, Mexico, and the
Philippines codifies the most principles for access to
medicines.
Three trends for access to medicines were more
common, although not significant, in the legislation
of upper-middle and high income countries than the
low- and lower-middle income countries samples.
These trends are: (a) affluent countries (i.e. upper-
middle and high income countries) embed explicit
individual rights and state obligations about medi-
cines in national law; (b) affluent countries establish
in law clear boundaries to these entitlements and
obligations; (c) affluent countries codify mechanisms
for accountability and redress in national law. A full
explanation of these observations is available else-
where [56]. These trends generate hypotheses to be
tested in a larger sample of countries.
Part 2: ‘lawmaking’ for access to medicines
through Uruguayan courts
Of the 42 claims included in this study, 31 (74%)
were decided in favour of the claimant (i.e. usually
the patient); 34 claims (81%) accounted for 10 med-
icines; eight claims (19%) successfully acquired the
non-reimbursed medicines cetuximab, lenalidomide,
and sorafenib. Interestingly, these medicines were
explicitly excluded from the national medicines for-
mulary by Ministerial Order 86/2015 because they are
cost-ineffective for their indications. Complete results
are reported elsewhere [48].
In the judicial decisions in this sample, the
court inconsistently interpreted patients’ rights
and the State’s legal obligations in line with the
right to health. Two similar claims for cetuximab
for the treatment of metastatic colon cancer
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illustrate this inconsistency. In the first case,
Appeals Circuit/Court 7 found that a lack of cost-
effectiveness did not justify denying reimburse-
ment to a patient who could not otherwise afford
the medicine (10 October 2015). Later, Appeals
Circuit/Court 5 decided that excluding the medi-
cine from reimbursement on economic grounds is
consistent with the patient’s right to health
(3 November 2015). (NB: There are seven cir-
cuits/courts of appeal. Medicines claims are ran-
domly assigned to a circuit.) The court’s decisions
to reimburse expensive medicines contradicted
the national rules for medicines selection and
financing (i.e. Ministerial Order 86/2015), and
sometimes also human rights principles in the
ICESCR and General Comment No. 14.
Part 3: access to medicines indicators in the
health system ‘environment’
Only half of the expected data points were retrievable.
No country reported data for all eight indicators,
therefore the denominator (number of countries
from which data could be retrieved) changes for
each indicator reported below. Constitutional recog-
nition for access to medicines was reported in part 1.
By 2015, 123/157 countries (78%) adopted an official
national medicines policy and 107/173 countries
(62%) had an essential medicines lists. See Figure 2.
The average national public spending on pharma-
ceuticals per capita ranged from US $0.51/year
($0.00-$17.56) in low income, $4.35/year
($0.00-$17.56) in lower-middle, $16.13/year ($10.01-
$71.82) in upper-middle, and $286.40/year ($2.94-
$601.42) in high-income countries. To determine
whether government spending was sufficient, govern-
ment reports were compared to the the $12.90/capita
annual minimum threshold to provide a basket of 201
essential medicines, as determined by the Lancet
Commission on Essential Medicines Policies [3].
Spending was above the threshold in few low- and
lower-middle income countries (except Afghanistan,
Morocco, Iraq, and Tuvalu), and in most upper-
middle and high-income countries (except in Gabon
and the Seychelles).
The median availability of a selection of lowest-
price generic medicines surveyed is slightly higher in
private facilities than in public centres. See Figure 3.
Median availability rarely met the 80% global target,
except in a republic of Russia (both sectors) and in
the private sector of Afghanistan, Tajikistan, Sudan,
and Boston, USA.
National measles immunisation rates met or
exceeded the 95% global coverage target to eradicate
the disease, in 39% (59/153) of all countries studied
(medianLICs = 58.5%, interquartile range (IQR) 79.5–
95.0%, nLICs = 12 countries; medianLMICs = 82.0%,
IQRLMICs = 59.3–94.0%, nLMICs = 36;
medianUMICs = 93.0%, IQRUMICs = 81.0– 97.5%,
nUMICs = 53; medianHICs = 92.0%, IQRHICs = 88.0–
96.0%, nHICs = 52).
National diphtheria-tetanus-pertussis immunisa-
tion rates met or exceeded the 90% global target in
43% (42/98) of all countries studied (medianLICs
= 84%, interquartile range (IQR) 63-93%, nLICs = 33
countries; medianLMICs = 86%, IQRLMICs = 66-95%,
nLMICs = 44; medianUMICs = 91%, IQRUMICs = 83-
95%, nUMICs = 21). Data was only available from one
high income country (Equatorial Guinea, 41% DTP3
coverage).
Discussion
This article demonstrates that human rights princi-
ples and WHO policy have been embedded in
Figure 2. Proportion of countries with a constitution that recognises access to medicines, a national medicines policy, or
a national essential medicines list.
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national law and policy for essential medicines and
practically implemented in national health systems.
Part 1 presents the first systematic, cross-national
content analyses of different legal documents relevant
for access to medicines, and examples of essential
medicines and human rights principles in national
law and policy. Some, but not all, of the 12 policy
points in the analytical framework are embedded in
domestic UHC law and national medicines policies.
This research presents innovative ideas for embed-
ding language promoting access to medicines in
national constitutions, medicines policies and UHC
legislation. National policy makers can use the exam-
ple texts in this thesis (found in Annexes 1 and 2) as
a starting point for designing national law and policy.
In part 2, the case study of Uruguay shows that
even the most rights-compliant legislation for access
to medicines (determined in part 1) is subject to the
unique and inconsistent interpretation of domestic
courts. The decisions of national judiciaries can
diverge, sometimes dramatically, from globally-
accepted interpretations of the right to health. These
findings show that medicines litigation in Uruguay
offers relief for some individual patients, but fails to
address the structural problems behind high medi-
cines prices. More generally, this study illustrates that
both the black-and-white letter of national law, as
well as domestic courts’ interpretations of that law,
should be considered when determining to what
degree a legal system takes a human rights approach
towards essential medicines.
Part 3 reports on States’ achievement of their right
to health obligations for essential medicines in 2015
at the dawn of the 2030 Agenda for Sustainable
Development. Many countries for which data were
available still fail to meet the official targets. These
findings offer an updated reference point to measure
future achievements on essential medicines as part of
the right to health under the SDGs. The challenges of
monitoring access to medicines globally, highlighted
during the tenure of the Millennium Development
Goals, regrettably persist in the era of Sustainable
Development [24,25]. This monitoring study helps
move modern human rights practice beyond the tra-
dition of ‘naming, shaming, and litigating’ rights vio-
lations towards real-time measuring and monitoring
rights realisation [57].
Theory and practice: the effect of national law
and policy on access to medicines
To the author’s knowledge, this thesis is currently the
most robust academic endeavour to develop the evi-
dence base to study the effect of national law and
policy on access to medicines in LMICs. A large body
of public health law implementation and evaluation
research exists, albeit mostly in the US context
[28,58,59,60,61,62]. These studies are often based on
reliable online repositories of legislation and policy in
English, implementation mechanisms described in
scholarship and understood in practice, and robust
datasets of outcome measures- all of which are com-
monly unavailable or underdeveloped in LMIC
contexts.
One of the most significant contributions this the-
sis makes is to map and critically analyse different
types of national legislation and policies related to
access to medicines in LMICs, where there was pre-
viously little to no data readily available for analysis.
Importantly, this ‘policy mapping’ exercise used
transparent and reproducible methods, while coding
and describing the 12 policy measures being studied,
providing data for future research. As suggested by
Scott Burris and colleagues, future studies can use the
legislation and policy presented in this article as an
outcome of policymaking studies (i.e. to understand
the determinants of the policymaking process) as well
as an independent variable in evaluation research (i.e.
to examine the impact of law) [28]. This thesis criti-
cally analysed the content of national law and policy
using a framework that is comparable across jurisdic-
tions, types of legal instruments, and time.
Part 2 of this study examines lawmaking by judges.
This study has shown that how judges understand
Figure 3. Median national availability of lowest priced generics in the public and private sectors, 2008–2015. Data source:
Health Action International. Medicine Prices, Availability, Affordability and Price Components [online database] Available from:
http://www.haiweb.org/medicineprices/.
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international human rights law, and specifically the
right to health, has important implications for how
national law will be interpreted and, ultimately,
whether patients will receive government-financed
medicines.
The eight indicators of access to medicines in part
3 offer useful insight into their feasibility as depen-
dent variables in future evaluation studies examining
the impact of national law and policy.This study also
demonstrates that reliable data from national health
systems- a crucial ingredient for evaluation studies- is
scarce in many countries. The question also arises of
whether these eight indicators are the best proxy
measures of changes in access to medicines in health
systems. Further discussion about suitable indicators
to evaluate access to medicines is available else-
where [63].
Future research
One question not addressed by this study but worthy
of future research is: what effect do rights-based legal
provisions in national law and policy have on access to
medicines in health systems and on broader population
health outcomes? Scott Burris notes that comparative
policy analysis in the context of public health is
under-theorised yet it has a rich diversity of policy
aspects under study, implementation processes, and
outcomes [29]. The field of access to medicines is no
different. Implementation research is essential to
understand how law and policy for access to medi-
cines is translated into desired results, both in terms
of the health system (i.e. financing and availability of
medicines) and population health outcomes (i.e. mor-
bidity and mortality rates). Piecemeal evidence sug-
gests that a constitutional right to health may shape
the ‘institutional environment’, leading to increased
and better health service delivery, and it may lead to
increased public spending on healthcare [64,65].
However, there is need for compelling and authori-
tative studies confirming a causal relationship
between a constitutional/legal right to health, changes
in the health system environment, and positive health
outcomes. Research should also investigate the
mechanisms by which national law and policy achieve
intermediate outcomes (i.e. better access to medi-
cines) and population-level impacts.
Impact on policy
Currently, WHO’s Guide for developing and imple-
menting a national medicines policy (2001) omits any
mention of a government obligation to provide essen-
tial medicines to those who can not provide for
themselves (a cornerstone of the right to health and
the UHC concept). Moreover, WHO does not have
any specific guidance for Member States to write or
reform national legislation promoting universal
access to medicines in UHC schemes, which is cur-
rently the subject of high-level political declarations
and dominant debate in global health policy. In light
of these gaps, WHO should develop modern gui-
dance documents for the UHC era using the 12-
point policy checklist and examples of legal text
from this thesis as a starting point. Some of these
examples translate the recommendations of the
WHO Consultative Group on Equity and UHC for
making fair choices on the path to UHC into legal
provisions for national law [10]. This thesis may also
assist WHO to develop model legislation for medi-
cines reimbursement, which is goal 7 of WHO’s
2016–2030 Medicines & Health Products Strategic
Programme [11].
WHO should establish an online repository of
national health law in order to centralise the results of
these legal mapping exercises. In this repository, legal
texts in their original language and translations in
English or other UN language can be deposited and
publicly consulted. To enhance human rights monitor-
ing and reporting, Member States should self-report on
two principles for access to medicines when they
deposit legislation: 1) government financing for medi-
cines for the poor and vulnerable groups, and 2) mea-
sures to control medicines prices (i.e. prioritising
medicines reimbursement based on cost-effectiveness,
use of pricing policies and/or TRIPS Flexibilities).
Indicator 1 ensures a government duty to provide
essential medicines to those who can not provide for
themselves- the crux of ‘core obligations’ under the
right to health. Indicator 2 can help set objective bound-
aries to the right to health, and protect against unrea-
sonable patient requests and spurious litigation for high
priced medicines. A concise self-report is a quick snap-
shot of legal provisions; it is less laborious than an entire
country profile and can be verified by consulting the
laws in the repository.
National policy makers from the executive and
legislative branches can preform their own monitor-
ing exercise using the 12-point policy checklist to
evaluate national law and policy for medicines. This
exercise can identify gaps or weaknesses in existing
law for improvement through future reform. The
example legal texts in this thesis can be a source of
inspiration for legislators writing or amending
national law or policy. Moreover, national policy
makers should adopt and finance a monitoring and
reporting plan for indicators of access to medicines in
line with the recommendations in this study and
from the Lancet Commission for Essential
Medicines Policies. Areas of deficiency should lead
to a documented plan for improvements within a set
timeframe.
Domestic judges should familiarise themselves with
the right to health and its interpretation in international
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human rights law, especially the concepts of essential
medicines selection and progressive realisation (i.e.
there is no immediate right to all available treatments
but a duty to continuously and gradually expand access)
[66]. Most importantly, domestic judges should interro-
gate whether the government has used a maximum of its
available resources to provide themedicine(s) in question
(part of the standard of reasonableness) before ordering
the public to pay for it [14]. Such a reasonableness test
should lead to enhanced government action to reduce
medicines prices and more efficient use of public
resources to finance medicines.
Strengths and limitations
This thesis is the first systematic enquiry into
national law and policy for access to medicines in
LMICs. Data collection drew from reputable repo-
sitories of constitutional and case law, and second-
ary datasets from Health Action International’s
medicines pricing database and WHO/UNICEF,
among others. National medicines policies and
health legislation were collected using systematic
online search and crowdsourcing methods, and
a data extraction template. UHC legislation was
collected from a purposive sample of 16 countries,
which is the largest known comparison of UHC
legislation from LMICs. These steps minimised the
risk of a reporting bias. In summary, this study has
assembled the most comprehensive collection of
full-text national medicines policies and domestic
health legislation for medicines from LMICs to date.
Little data for indicators of access to medicines was
available for government financing and medicines
availability in both sectors, and for countries in cer-
tain economic categories. Compared to the 2008
report of these indicators, this thesis uses the same
methodology (in as far as possible) and reports data
from more countries.
One significant strength of this study is its reliance
on primary sources of national law and policy, which
are more objective than the common practice of
reporting key informants’ own interpretations of leg-
islation and policy. Using national law and policy in
its original language raises the question of correct
translation to English and interpretation within the
local legal context. To address these issues, multi-
lingual and multidisciplinary research teams trained
in law and medicine collected national laws and poli-
cies, and then extracted, translated and analysed
relevant legal provisions. To ensure the correct inter-
pretation of national law and policies, this study used
an analytical framework based on global standards in
WHO’s essential medicines policies and international
human rights law. These global standards establish
clear, standard definitions and legal concepts that
have the greatest chance of being consistent over
time and across policy/legal instruments. Therefore,
unless otherwise stated in the definitions section of
national law and policy, it was reasonably assumed
that the terminology and concepts unique to these
global standards are broadly understood in the same
way in national law and policy. Second, at least one
national pharmaceutical policy expert per country
(except for Algeria and Nigeria) was consulted to
confirm that all relevant national law and medicines
policies had been located and accurately understood.
Conclusion
International human rights law imparts important
principles that are commonly embedded in the text
of national law and policy for access to medicines and
traceable through proxy indicators in health systems.
This thesis offers researchers and policy makers the
tools and the examples to translate human rights law
and WHO’s essential medicines policies into national
legal commitments and to monitor government
actions for universal access to essential medicines as
part of SDG Target 3.8. It can also inform WHO’s
future guidance on UHC and essential medicines.
This thesis assembled the essential building blocks
to study and generated hypotheses to test the effect
of national law and policy on access to medicines and
population health in LMICs.
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